drugset / Trial / NCT00217139

A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

NCT00217139

Phase 2 Completed 60 enrolled BioWest Therapeutics Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Timeline

Start
2005-09
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Celgosivir Small molecule